Peter S Kirk1, Shail Govani2, Tudor Borza1, Brent K Hollenbeck1, Jennifer Davis3, Dean Shumway4, Akbar K Waljee5, Ted A Skolarus6. 1. Dow Division of Health Services Research, Department of Urology, University of Michigan Health System, Ann Arbor, MI. 2. Department of Gastroenterology, Division of Internal Medicine, University of Michigan Health System, Ann Arbor, MI. 3. VA Health Services Research and Development, Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI. 4. Department of Radiation Oncology, University of Michigan Health System, Ann Arbor, MI. 5. Department of Gastroenterology, Division of Internal Medicine, University of Michigan Health System, Ann Arbor, MI; VA Health Services Research and Development, Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI. 6. Dow Division of Health Services Research, Department of Urology, University of Michigan Health System, Ann Arbor, MI; VA Health Services Research and Development, Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI. Electronic address: tskolar@med.umich.edu.
Abstract
OBJECTIVE: To investigate the influences of inflammatory bowel disease (IBD), a rare but morbid disease with increasing incidence, on prostate cancer management decisions. We examined whether prostate cancer treatment differed for men with IBD, and whether treatment choice was associated with risk of IBD flare. MATERIALS AND METHODS: Using Veterans Health Administration cancer registry and administrative data, we identified 52,311 men diagnosed with prostate cancer from 2005 to 2008. We used International Classification of Diseases-9 codes and pharmacy and utilization data to identify IBD diagnoses, IBD-directed therapy, and flares (glucocorticoid escalation, hospitalization, and surgical intervention). We compared characteristics across men with and without IBD, and used multivariable regression to examine IBD flares after treatment according to treatment type. RESULTS: Two hundred and forty men (0.5%) had IBD prior to prostate cancer diagnosis. Compared to non-IBD patients, IBD patients were more likely Caucasian (P < .001) with lower-risk cancer (P = .02). Surgery was more common in IBD patients (41% vs 28%, P < .001). In the year following prostate cancer treatment, 18% of IBD patients experienced flares. After adjustment, the only predictor of flare in the year after treatment was flare in the year prior to treatment (adjusted odds ratio, 12.5; 95% confidence interval, 5.4-29.2). CONCLUSION: IBD patients were more likely to have lower-risk disease and be treated with surgery. Choice of prostate cancer treatment did not predict flares in the subsequent year. Better understanding of the intersection of IBD and prostate cancer can help inform treatment decisions for the increasing number of men managing both diseases. Published by Elsevier Inc.
OBJECTIVE: To investigate the influences of inflammatory bowel disease (IBD), a rare but morbid disease with increasing incidence, on prostate cancer management decisions. We examined whether prostate cancer treatment differed for men with IBD, and whether treatment choice was associated with risk of IBD flare. MATERIALS AND METHODS: Using Veterans Health Administration cancer registry and administrative data, we identified 52,311 men diagnosed with prostate cancer from 2005 to 2008. We used International Classification of Diseases-9 codes and pharmacy and utilization data to identify IBD diagnoses, IBD-directed therapy, and flares (glucocorticoid escalation, hospitalization, and surgical intervention). We compared characteristics across men with and without IBD, and used multivariable regression to examine IBD flares after treatment according to treatment type. RESULTS: Two hundred and forty men (0.5%) had IBD prior to prostate cancer diagnosis. Compared to non-IBD patients, IBD patients were more likely Caucasian (P < .001) with lower-risk cancer (P = .02). Surgery was more common in IBD patients (41% vs 28%, P < .001). In the year following prostate cancer treatment, 18% of IBD patients experienced flares. After adjustment, the only predictor of flare in the year after treatment was flare in the year prior to treatment (adjusted odds ratio, 12.5; 95% confidence interval, 5.4-29.2). CONCLUSION: IBD patients were more likely to have lower-risk disease and be treated with surgery. Choice of prostate cancer treatment did not predict flares in the subsequent year. Better understanding of the intersection of IBD and prostate cancer can help inform treatment decisions for the increasing number of men managing both diseases. Published by Elsevier Inc.
Authors: Lars Budäus; Michel Bolla; Alberto Bossi; Cesare Cozzarini; Juanita Crook; Anders Widmark; Thomas Wiegel Journal: Eur Urol Date: 2011-10-06 Impact factor: 20.096
Authors: Raina Shivashankar; William J Tremaine; W Scott Harmsen; Edward V Loftus Journal: Clin Gastroenterol Hepatol Date: 2016-11-14 Impact factor: 11.382
Authors: Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali Journal: Med Care Date: 2005-11 Impact factor: 2.983
Authors: Jason K Hou; Mimi Tan; Ryan W Stidham; John Colozzi; Devon Adams; Hashem El-Serag; Akbar K Waljee Journal: Dig Dis Sci Date: 2014-05-10 Impact factor: 3.199
Authors: Akbar K Waljee; Wyndy L Wiitala; Shail Govani; Ryan Stidham; Sameer Saini; Jason Hou; Linda A Feagins; Nabeel Khan; Chester B Good; Sandeep Vijan; Peter D R Higgins Journal: PLoS One Date: 2016-06-23 Impact factor: 3.240
Authors: Ben G L Vanneste; Evert J Van Limbergen; Tom Marcelissen; Kobe Reynders; Jarno Melenhorst; Joep G H van Roermund; Ludy Lutgens Journal: Clin Transl Radiat Oncol Date: 2021-01-25